# Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera

> **NCT07232290** · PHASE2 · RECRUITING · sponsor: **Chengdu Zenitar Biomedical Technology Co., Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Polycythemia Vera (PV)

## Interventions

- **DRUG:** Flonoltinib 75mg
- **DRUG:** Flonoltinib 100mg
- **DRUG:** Flonoltinib 125mg
- **DRUG:** Extended Phase Dose Group

## Key facts

- **NCT ID:** NCT07232290
- **Lead sponsor:** Chengdu Zenitar Biomedical Technology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-23
- **Primary completion:** 2027-07-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232290, "Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07232290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*